Aug 13, 2025 4:15pm EDT Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
Jul 31, 2025 8:00am EDT Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
Jul 16, 2025 8:00am EDT Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
Jun 24, 2025 8:00am EDT Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
Jun 04, 2025 8:00am EDT Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
Apr 24, 2025 4:15pm EDT Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Apr 23, 2025 4:41pm EDT Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds